Chromosomal Abnormalities in Myelodysplastic Syndromes Detected With Multiplex Ligation Dependent Probe Amplification

Detection of chromosomal abnormalities in myelodysplastic syndromes enables classification according to WHO Classification and risk stratification according to IPSS and R-IPSS, providing physicians with data regarding personal therapy approach. Detection of the chromosomal abnormalities in our cohort study was performed with the method Multiplex Ligation-dependent Probe Amplification is similar to multiplex PCR reactions, but in this case the target-sequences are amplificated, but MLPA probes hybridized for them. 70 patients, chromosomal abnormalities were detected in 32.9% patients, while 67.1% patients had normal findings. Patients were classified according to WHO and stratified according to IPSS and R-IPSS. Data obtained enabled us to make treatment strategy at diagnosis. There are different treatment options for different risk groups including allogeneic transplantation for high and very high risk patients as well as hypomethylating agents for those who are not candidates for transplantation. For low risk groups supportive treatment and growing factors were most often the choice.We can conclude that MLPA reliable method for detection of chromosomal abnormalities in myelodysplastic syndromes.